Paul Waako

Last updated

Paul Waako
Born (1967-02-20) 20 February 1967 (age 56)
Mukuta Village, Mayuge District, Uganda
Alma mater Makerere University
(Bachelor of Medicine and Bachelor of Surgery)
(Master of Science in Pharmacology) University of Cape Town
(Doctor of Philosophy in Clinical Pharmacology)
Uganda Management Institute
(Postgraduate Diploma in Management)
Occupation Vice Chancellor of Busitema University
Known forProfessional competence
Title Vice Chancellor of Busitema University

Professor Paul Waako (born 20 February 1967), is a Ugandan pharmacologist, academic and academic administrator, who serves as the Vice Chancellor of Busitema University, a public university in the Eastern Region of Uganda, since 1 May 2019. [1]

Contents

Background and education

Waako was born on 20 February 1967 at Mukuta Village, in Mayuge District, in the Eastern Region of Uganda. After attending local primary and secondary schools, he was admitted to Makerere University School of Medicine, the oldest medical school in East Africa. [1]

He holds a Bachelor of Medicine and Bachelor of Surgery degree and a Master of Science degree in Pharmacology, both awarded by Makerere University, in Uganda. His Doctor of Philosophy in Clinical Pharmacology was obtained from the University of Cape Town, in South Africa. He also holds a Postgraduate Diploma in Management, obtained from the Uganda Management Institute, in Kampala. [1]

Career

For a period of ten years, he chaired the Department of Pharmacology and Therapeutics at Makerere University College of Health Sciences. He was then appointed Dean of Busitema University Faculty of Health Sciences, serving in that capacity from 2013 until 2019. [1]

As Vice Chancellor at Busitema University, he succeeded Professor Mary Okwakol, the founding Vice Chancellor, whose term of office ended on 30 April 2019. [2]

Family

Professor Waako is married to Engineer Ziria Tibalwa Waako, an electrical engineer, who serves as the chief executive officer of Uganda's Electricity Regulatory Authority, since November 2016. Together, they are parents to five children. [3]

Other considerations

He has published extensively in the areas of traditional medicines, drug discovery and development, rational use of medicines, and medicine supply systems. He has over 50 publications in peer reviewed Journals to his name. He is a Senior Research Fellow at Queen Mary University of London. He is also a Fellow of the Uganda National Academy of Sciences. [1] [2] [3] Some of the publications include; Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda. The study found that prevalence of THM use among participants on HAART was high. [4] Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicators. The study evaluated the feasibility of collecting routine data to standardize adherence measurement using a draft set of indicators. [5] Traditional treatment of malaria in Mbarara District, western Uganda. [6] East African medicinal plants as a source of lead compounds for the development of new antimalarial drugs. [7] A strategy to improve skills in pharmaceutical supply management in East Africa: the regional technical resource collaboration for pharmaceutical management. The study established that the ability of trained institutions to mobilize their own resources for skills-building activities is crucial for the success and sustainability of these programmes. [8] Existing capacity to manage pharmaceuticals and related commodities in East Africa: an assessment with specific reference to antiretroviral therapy. Among others the study established that there is inadequate capacity for managing medicines and related commodities in East Africa. [9] A comparison of prescribing practices between public and private sector physicians in Uganda. [10] A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. [11] Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda. This study established that plant based therapies for treating TB were identified. [12] Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. The study concluded that efavirenz related neuropsychiatric symptoms are common among Ugandan HIV patients receiving ART. [13] The prevalence and severity of mental illnesses handled by traditional healers in two districts in Uganda. [14] The anti-mycobacterial activity of Lantana camara a plant traditionally used to treat symptoms of tuberculosis in South-western Uganda. [15] Factors predicting home storage of medicines in Northern Uganda. The study established that self-medication is common among individuals in households which keep drugs. [16] Psychological distress and associated factors among the attendees of traditional healing practices in Jinja and Iganga districts, Eastern Uganda: a cross-sectional study. The study provided evidence that a substantial proportion of attendees of traditional healing practices suffer from psychological distress. [17] Patterns and Predictors of Self-Medication in Northern Uganda. [18] The in vitro and in vivo antimalarial activity of Cardiospermum halicacabum L. and Momordica foetida Schumch. Et Thonn. [19] Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda. The study identified numerous medicinal plants for treatment of HIV/AIDS patients were identified in the four districts. [20]

See also

Related Research Articles

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

<span class="mw-page-title-main">HIV/AIDS in Africa</span> HIV/AIDS in Africa

HIV/AIDS originated in the late 20th century and has been a major public health concern and cause of death in many countries. AIDS rates varies significantly between countries, though the majority of cases are concentrated in Southern Africa. Although the continent is home to about 15.2 percent of the world's population, more than two-thirds of the total population infected worldwide – some 35 million people – were Africans, of whom c.1 million have already died. Eastern and Southern Africa alone accounted for an estimate of 60 percent of all people living with HIV and 100 percent of all AIDS deaths in 2011. The countries of Eastern and Southern Africa are most affected, AIDS has raised death rates and lowered life expectancy among adults between the ages of 20 and 49 by about twenty years. Furthermore, the life expectancy in many parts of Africa is declining, largely as a result of the HIV/AIDS epidemic with life-expectancy in some countries reaching as low as thirty-nine years.

<span class="mw-page-title-main">Tenofovir disoproxil</span> Antiviral drug used to treat or prevent HIV and hepatitis infections

Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention of HIV/AIDS among those at high risk before exposure, and after a needlestick injury or other potential exposure. It is sold both by itself and together in combinations such as emtricitabine/tenofovir, efavirenz/emtricitabine/tenofovir, and elvitegravir/cobicistat/emtricitabine/tenofovir. It does not cure HIV/AIDS or hepatitis B. It is available by mouth as a tablet or powder.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

<span class="mw-page-title-main">Efavirenz</span> Antiretroviral medication

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth.

<span class="mw-page-title-main">CYP2B6</span> Protein-coding gene in the species Homo sapiens

Cytochrome P450 2B6 is an enzyme that in humans is encoded by the CYP2B6 gene. CYP2B6 is a member of the cytochrome P450 group of enzymes. Along with CYP2A6, it is involved with metabolizing nicotine, along with many other substances.

<span class="mw-page-title-main">HIV disease–related drug reaction</span>

HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.

<span class="mw-page-title-main">Traditional African medicine</span> Traditional medical practices in Africa

Traditional African medicine is a range of traditional medicine disciplines involving indigenous herbalism and African spirituality, typically including diviners, midwives, and herbalists. Practitioners of traditional African medicine claim, largely without evidence, to be able to cure a variety of diverse conditions including cancer, psychiatric disorders, high blood pressure, cholera, most venereal diseases, epilepsy, asthma, eczema, fever, anxiety, depression, benign prostatic hyperplasia, urinary tract infections, gout, and healing of wounds and burns and Ebola.

The co-epidemic of tuberculosis (TB) and human immunodeficiency virus (HIV) is one of the major global health challenges in the present time. The World Health Organization (WHO) reports 9.2 million new cases of TB in 2006 of whom 7.7% were HIV-infected. Tuberculosis is the most common contagious infection in HIV-Immunocompromised patients leading to death. These diseases act in combination as HIV drives a decline in immunity while tuberculosis progresses due to defective immune status. This condition becomes more severe in case of multi-drug (MDRTB) and extensively drug resistant TB (XDRTB), which are difficult to treat and contribute to increased mortality. Tuberculosis can occur at any stage of HIV infection. The risk and severity of tuberculosis increases soon after infection with HIV. A study on gold miners of South Africa revealed that the risk of TB was doubled during the first year after HIV seroconversion. Although tuberculosis can be a relatively early manifestation of HIV infection, it is important to note that the risk of tuberculosis progresses as the CD4 cell count decreases along with the progression of HIV infection. The risk of TB generally remains high in HIV-infected patients, remaining above the background risk of the general population even with effective immune reconstitution and high CD4 cell counts with antiretroviral therapy.

Celestino Obua is a Ugandan physician, pharmacologist, academic and academic administrator. He is the current Vice Chancellor of Mbarara University of Science and Technology. He assumed that position on Friday, 24 October 2014. Prior to that, he served as the Deputy Principal of Makerere University College of Health Sciences.

Harriet Mayanja-Kizza, MBChB, MMed, MSc, FACP, is a Ugandan physician, researcher, and academic administrator. She is the former Dean of Makerere University School of Medicine, the oldest medical school in East Africa, established in 1924.

<span class="mw-page-title-main">Elioda Tumwesigye</span> Ugandan politician

Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. From March 2015 until June 2016, he served as the minister of health.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

Moses R Kamya, is a Ugandan physician, academic, researcher and academic administrator, who serves as Professor and Chair of the Department Medicine, Makerere University School of Medicine, a component of Makerere University College of Health Sciences.

Rhoda Wanyenze is a physician, public health consultant, academic and medical administrator, who serves as the Dean of Makerere University School of Public Health, a component school of Makerere University College of Health Sciences, which is part of Makerere University, Uganda's oldest and largest public university.

Elizabeth Anne Bukusi FAAS is a research professor working within the field of obstetrics and gynaecology, and global health. Bukusi's main areas of research focus around sexually transmitted infections, women's health, reproductive health, and HIV care, prevention and treatment. Bukusi is the Chief Research Officer at the Kenya Medical Research Institute (KEMRI) and led a "landmark" study on the use of PrEP in Kenya.

<span class="mw-page-title-main">Annie Luetkemeyer</span> American physician and infectious diseases researcher

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV.

Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute and a Honorary Senior lecturer at Makerere University College of Sciences. He is also an Adjunct Associate Professor at the University of Minnesota. In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.

Damalie Nakanjako, is a Ugandan specialist physician, internist, immunologist, infectious diseases consultant, academic and researcher, who serves as the Principal and Professor of Medicine at Makerere University College of Health Sciences. Immediately prior to her present position, she served as Dean of Makerere University School of Medicine, from 2019 until 17 February 2021.

<span class="mw-page-title-main">Charles Flexner</span> American physician and pharmaceutical scientist

Charles Williams Flexner is an American physician, clinical pharmaceutical scientist, academic, author and researcher. He is a Professor of Medicine at the Johns Hopkins University School of Medicine.

References

  1. 1 2 3 4 5 George Okello (4 March 2019). "Prof Waako Appointed New Busitema University Vice Chancellor". Kampala: PML Daily. Retrieved 4 November 2019.
  2. 1 2 Philimon Badagawa (11 March 2019). "Prof. Paul Waako to takeover from Prof. Mary Okwakol as Vice Chancellor of Busitema University". Kampala: Campus Times Uganda. Retrieved 4 November 2019.
  3. 1 2 Busitema University (June 2019). "Profile of Professor Paul Waako: Vice Chancellor Busitema University". Busitema University . Retrieved 4 November 2019.
  4. ↑ Namuddu, Betty; Kalyango, Joan N.; Karamagi, Charles; Mudiope, Peter; Sumba, Samwel; Kalende, Henry; Wobudeya, Eric; Kigozi, Brian K.; Waako, Paul (10 November 2011). "Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda". BMC Public Health. 11 (1): 855. doi: 10.1186/1471-2458-11-855 . ISSN   1471-2458. PMC   3270112 . PMID   22074367.
  5. ↑ Chalker, John C.; Andualem, Tenaw; Gitau, Lillian N.; Ntaganira, Joseph; Obua, Celestino; Tadeg, Hailu; Waako, Paul; Ross-Degnan, Dennis; INRUD-IAA (19 February 2010). "Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicators". BMC Health Services Research. 10 (1): 43. doi: 10.1186/1472-6963-10-43 . ISSN   1472-6963. PMC   2836318 . PMID   20170479.
  6. ↑ Katuura, E.; Waako, P.; Ogwal-Okeng, J.; Bukenya-Ziraba, R. (2007). "Traditional treatment of malaria in Mbarara District, western Uganda". African Journal of Ecology. 45 (s1): 48–51. Bibcode:2007AfJEc..45S..48K. doi:10.1111/j.1365-2028.2007.00737.x. ISSN   0141-6707.
  7. ↑ Waako, P. J.; Katuura, E.; Smith, P.; Folb, P. (2007). "East African medicinal plants as a source of lead compounds for the development of new antimalarial drugs". African Journal of Ecology. 45 (s1): 102–106. Bibcode:2007AfJEc..45S.102W. doi: 10.1111/j.1365-2028.2007.00752.x . ISSN   0141-6707.
  8. ↑ Matowe, Lloyd; Waako, Paul; Adome, Richard Odoi; Kibwage, Isaac; Minzi, Omary; Bienvenu, Emile (23 December 2008). "A strategy to improve skills in pharmaceutical supply management in East Africa: the regional technical resource collaboration for pharmaceutical management". Human Resources for Health. 6 (1): 30. doi: 10.1186/1478-4491-6-30 . ISSN   1478-4491. PMC   2630320 . PMID   19105836.
  9. ↑ Waako, Paul J.; Odoi-adome, Richard; Obua, Celestino; Owino, Erisa; Tumwikirize, Winnie; Ogwal-okeng, Jasper; Anokbonggo, Willy W.; Matowe, Lloyd; Aupont, Onesky (9 March 2009). "Existing capacity to manage pharmaceuticals and related commodities in East Africa: an assessment with specific reference to antiretroviral therapy". Human Resources for Health. 7 (1): 21. doi: 10.1186/1478-4491-7-21 . ISSN   1478-4491. PMC   2662782 . PMID   19272134.
  10. ↑ Ogwal-Okeng, J W; Obua, C; Waako, P; Aupont, O; Ross-Degnan, D (1 February 2004). "A comparison of prescribing practices between public and private sector physicians in Uganda". East African Medical Journal. Suppl: S12–6. ISSN   0012-835X. PMID   15125111.
  11. ↑ Mukonzo, Jackson K.; Röshammar, Daniel; Waako, Paul; Andersson, Maria; Fukasawa, Takashi; Milani, Lili; Svensson, Jan Olof; Ogwal-Okeng, Jasper; Gustafsson, Lars L.; Aklillu, Eleni (2009). "A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans: Efavirenz population pharmacokinetic/pharmacogenetic modelling". British Journal of Clinical Pharmacology. 68 (5): 690–699. doi:10.1111/j.1365-2125.2009.03516.x. PMC   2791975 . PMID   19916993.
  12. ↑ Bunalema, Lydia; Obakiro, Samuel; Tabuti, John R. S.; Waako, Paul (3 February 2014). "Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda". Journal of Ethnopharmacology. 151 (2): 999–1004. doi:10.1016/j.jep.2013.12.020. ISSN   0378-8741. PMID   24365640.
  13. ↑ Mukonzo, Jackson K.; Okwera, Alphonse; Nakasujja, Neoline; Luzze, Henry; Sebuwufu, Deogratious; Ogwal-Okeng, Jasper; Waako, Paul; Gustafsson, Lars L.; Aklillu, Eleni (4 June 2013). "Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study". BMC Infectious Diseases. 13 (1): 261. doi: 10.1186/1471-2334-13-261 . ISSN   1471-2334. PMC   3680019 . PMID   23734829.
  14. ↑ Abbo, C.; Ekblad, S.; Waako, P.; Okello, E.; Musisi, S. (2009). "The prevalence and severity of mental illnesses handled by traditional healers in two districts in Uganda". African Health Sciences. 9 (2): S16-22. doi:10.4314/ahs.v9i2.47807 (inactive 31 January 2024). ISSN   1729-0503. PMC   2890991 . PMID   20589155.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  15. ↑ Kirimuhuzya, C.; Waako, P.; Joloba, M.; Odyek, O. (20 March 2009). "The anti-mycobacterial activity of Lantana camara a plant traditionally used to treat symptoms of tuberculosis in South-western Uganda". African Health Sciences. 9 (1): 40–45. doi:10.4314/ahs.v9i1.7101 (inactive 31 January 2024). ISSN   1729-0503. PMC   2932521 . PMID   20842241.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  16. ↑ Ocan, Moses; Bbosa, Godfrey S.; Waako, Paul; Ogwal-Okeng, Jasper; Obua, Celestino (26 June 2014). "Factors predicting home storage of medicines in Northern Uganda". BMC Public Health. 14 (1): 650. doi: 10.1186/1471-2458-14-650 . ISSN   1471-2458. PMC   4229978 . PMID   24964746.
  17. ↑ Abbo, Catherine; Ekblad, Solvig; Waako, Paul; Okello, Elialilia; Muhwezi, Wilson; Musisi, Seggane (23 December 2008). "Psychological distress and associated factors among the attendees of traditional healing practices in Jinja and Iganga districts, Eastern Uganda: a cross-sectional study". International Journal of Mental Health Systems. 2 (1): 16. doi: 10.1186/1752-4458-2-16 . ISSN   1752-4458. PMC   2621117 . PMID   19105804.
  18. ↑ Ocan, Moses; Bwanga, Freddie; Bbosa, Godfrey S.; Bagenda, Danstan; Waako, Paul; Ogwal-Okeng, Jasper; Obua, Celestino (21 March 2014). "Patterns and Predictors of Self-Medication in Northern Uganda". PLOS ONE. 9 (3): e92323. Bibcode:2014PLoSO...992323O. doi: 10.1371/journal.pone.0092323 . ISSN   1932-6203. PMC   3962384 . PMID   24658124.
  19. ↑ Waako, P. J.; Gumede, B.; Smith, P.; Folb, P. I. (13 May 2005). "The in vitro and in vivo antimalarial activity of Cardiospermum halicacabum L. and Momordica foetida Schumch. Et Thonn". Journal of Ethnopharmacology. 99 (1): 137–143. doi:10.1016/j.jep.2005.02.017. ISSN   0378-8741. PMID   15848033.
  20. ↑ Lamorde, Mohammed; Tabuti, John R. S.; Obua, Celestino; Kukunda-Byobona, Collins; Lanyero, Hindam; Byakika-Kibwika, Pauline; Bbosa, Godfrey S.; Lubega, Aloysius; Ogwal-Okeng, Jasper; Ryan, Mairin; Waako, Paul J.; Merry, Concepta (6 July 2010). "Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda". Journal of Ethnopharmacology. 130 (1): 43–53. doi:10.1016/j.jep.2010.04.004. hdl: 2262/39981 . ISSN   0378-8741. PMID   20451595.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.